SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Acquisition

2 Sep 2010 07:00

RNS Number : 0180S
McBride PLC
02 September 2010
 



2 September 2010

 

McBride plc

 

McBride plc announces the acquisition of Dermacol a.s., a manufacturer of skincare products based in the Czech Republic.

 

McBride plc ("McBride"), Europe's leading provider of Private Label Household and Personal Care products, today announces the acquisition of a 70% interest in Dermacol a.s. ("the Company"), a privately owned, Czech-based manufacturer of skincare products for an expected consideration of around CZK240 million (£8 million) from its parent company Alphaduct a.s. ("Alphaduct"). McBride has also agreed to purchase the remaining 30% of the shares in late 2017 for a consideration based on the Company's operating profit in the 2017 financial year.

 

Acquisition highlights

 

·; Provides McBride with an established private label product range in the largest sector of the European Personal Care market.

 

·; Creates the base for future growth in our skincare business.

 

·; Expands our presence in the growing Central European markets in a low-cost location.

 

Information on Dermacol a.s.

 

Dermacol a.s. is a manufacturer of skincare products, including face creams, skin cleansers, sun care products, body lotions, hand creams and foot creams. Its sales are evenly split between private label products for supermarkets and pharmacy chains and branded products for Alphaduct, which are sold in the Czech Republic and certain other markets. As part of the acquisition agreement, Alphaduct remains the owner of the Dermacol brand and trademarks and it will continue the distribution and marketing of its branded products. Alphaduct has entered into an agreement with the Company to purchase a minimum volume of product on a cost plus basis until 2018.

 

The Company has one factory, which is based near Brno in the Czech Republic and employs over 100 people. It is a modern, well invested factory with significant capacity for expansion. The factory meets ISO 9001 standards and GMP standards required by customers.

 

During the year ended 31 December 2009, the Company reported profit before tax of CZK24 million (£0.8 million). At 31 December 2009, gross assets were CZK 312 million (£10.4 million).

 

Terms of the acquisition

 

The consideration for the initial 70% of the Company's shares comprises:

i. a first payment today of CZK 70 million in cash (£2.3 million); plus

ii. a second payment of CZK 54 million in cash (£1.9 million) payable in August 2011; plus

iii. a further five payments, in cash, payable from 2013 to 2017 inclusive, based on the Company's sales during the period.

 

The expected total consideration of CZK240 million (£8 million) for the initial 70% of shares of the Company will be made from existing Group resources.

 

The remaining 30% of the shares in the Company will be acquired by McBride following the end of the 2017 fiscal year based on the Company's operating profits in that year. The total consideration for the company cannot exceed CZK650 million (£21.7 million).

 

Strategic rationale for the acquisition

 

McBride's strategy is to lead the development of private label household and personal care products in Europe through a focus on organic growth, supplemented by selected acquisitions. Skincare represents 33% of the total European Personal Care market, and is estimated to be worth over 1.1 billion Euros at RSP. Growth of private label has exceeded total personal care growth in the last four years.

 

The Company provides McBride with a range of skincare development and manufacturing capabilities which is highly complementary to its current personal care range. It also provides McBride with a modern, flexible manufacturing plant in a cost competitive region of Europe. The Company will contribute to the significant private label skincare sales forecast for the McBride group, in particular in the UK, France and Germany.

 

Commenting on the acquisition, McBride's chief executive Chris Bull, said:

 

"I am delighted that we have been able to acquire such a high quality skincare company. It is consistent with our stated corporate strategy and provides McBride with a full range of products to create private label skincare ranges for our customers."

 

 

For further information please contact:

 

McBride plc

Chris Bull, Chief Executive

0207 539 7850

Richard Armitage, Finance Director

0207 539 7851

Financial Dynamics

Edward Bridges/Marc Cohen,

020 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQKKDDQFBKDCCK
Date   Source Headline
6th Feb 20267:00 amRNS-RInvestor Webinar on 26 February 2026
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTransaction in Own Shares
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTrading Update
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares
24th Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 202511:37 amRNSHolding(s) in Company
22nd Dec 202511:37 amRNSHolding(s) in Company
22nd Dec 202511:35 amRNSHolding(s) in Company
22nd Dec 202511:35 amRNSHolding(s) in Company
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20253:49 pmRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSLaunch of share buyback programme
28th Nov 20256:29 pmRNSRedemption of B Shares and Total Voting Rights
27th Nov 202512:27 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20254:40 pmRNSAGM Statement
20th Nov 20257:00 amRNSAGM Trading Update and Share Buyback

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.